Amarante, I. et al. (2025) “Full recovery over one year of the overlap syndrome scleromyositis to maintenance therapy with mycophenolate mofetil and rituximab, which relapsed within 8 months of discontinuation”, European Journal of Case Reports in Internal Medicine, 12(5). doi:10.12890/2025_005154.